Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia
- Rita Assi,
- Guillermo Garcia-Manero,
- Farhad Ravandi,
- Gautam Borthakur,
- Naval G. Daver,
- Elias Jabbour
- University of Texas MD Anderson Cancer Center
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOpen access
Sustainable Development Goals
- SDG 3 Good Health and Well
Abstract
<p>Background: The immune-mediated destruction of hematopoietic stem cells is implicated in the pathophysiology of aplastic anemia (AA). Immunosuppressive therapy (IST) using antithymocyte globulin and cyclosporine is successful in this setting. Eltrombopag is active in patients with refractory AA, presumably by increasing the bone marrow progenitors. Methods: This phase 2 trial initially was designed to evaluate standard IST in newly diagnosed patients with severe AA and later was amended to add eltrombopag to simultaneously address immune destruction and stem cell depletion. The primary outcome was the overall response rate (ORR) at 3 months and 6 months. Results: A total of 38 patients were enrolled: 17 (45%) received IST alone and 21 (55%) received additional eltrombopag. The ORR was 74%. Patients receiving IST plus eltrombopag had a similar ORR (76% vs 71%; P =.72), complete remission rate (38% vs 29%; P =.73), and median time to response (84 days vs 57 days; P =.30) compared with those receiving IST alone. The 2-year overall survival rate in the IST group was 91% compared with 82% for those patients treated with IST plus eltrombopag (P =.82). No cumulative toxicities were noted after the addition of eltrombopag. Conclusions: The addition of eltrombopag to standard IST was well tolerated and resulted in similar responses.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 4192-4201 (10 pages)Journal (Volume, Issue Number)
Cancer (Volume 124, Issue 21)Publication milestones
- Published - 11/01/2018
Publication status
Published - 11/01/2018
ISSN
0008-543XPublication IDs
- Scopus: 85054707398
- PubMed: 30307606
- ORCID: /0000-0002-8636-1071/work/68888218
Publication metrics
Metrics
SciVal
FWCI
0.95
SciVal
Author count
16
SciVal
citations
11
SciVal
Paper percentile
83
Fractional count
1
Fractional count
0.06
Fractional count
15
Fractional count
0.94
Fractional count
1
Fractional count
1
PlumX, opens in new tab
Citation count
41
Captures
46
Funding Details
Supported in part by The University of Texas MD Anderson Cancer Center Support Grant P30 CA016672.
